Manzo Pharmaceuticals Inc (MNZO) 0.0014 $MNZO
Manzo Pharmaceuticals solidifies deal with USA based manufacturers to begin producing the company's lactose intolerance probiotic, Lacto-Freedom
PR Newswire - Thu Mar 24, 6:00AM CDT
Manzo Pharmaceuticals, Inc. (OTCPink:MNZO), today announced that it has solidified deals with GMP and FDA approved, USA based firms to handle manufacturing, and encapsulating and packaging the company's Lacto-Freedom(TM) probiotic.
Attention Shareholders: Manzo Pharmaceuticals Due Diligence Report - BrokerBank Securities
PR Newswire - Mon Oct 19, 7:15AM CDT
Manzo Pharmaceuticals, Inc. (OTCBB: MNZO) closed the trading at $.0007 up 133% on October 15th and promptly returned 28% on the following day. MNZO shares traded between $.001 and $.0017 for most of this year before hitting a low of $.0001 earlier this month.
Manzo Pharmaceuticals starts human laboratory testing of the company's lactose intolerance probiotic, Lacto-Freedom(TM)
PR Newswire - Thu Oct 15, 8:00AM CDT
Manzo Pharmaceuticals, Inc. (OTCPink:MNZO), today announced that in conjunction with Celprogen, Inc., the human laboratory testing of the company's exciting probiotic, Lacto-Freedom(TM) has begun. Celprogen has started sending out the test samples of the product marking the start of the much anticipated human testing, which is the last major step before the product can be manufactured and released to the public.
Manzo Pharmaceuticals announces exciting new product release as the company prepares for the full-scale human study of its Lacto-Freedom product to begin
PR Newswire - Mon Jun 08, 6:00AM CDT
Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced Manzo Pharmaceuticals has finished the development of its newest product, a natural sleep aid that the company has named Somnaid(TM). This news comes at the same time that Manzo Pharmaceuticals acknowledges positive results on its preliminary human study, and is now preparing to begin its full-scale human study of the company's ground breaking lactose intolerance product, Lacto-Freedom(TM).
Manzo Pharmaceuticals Announces Plans for Human Clinical Studies of the Company's Patented Lactose Intolerance Probiotic, Lacto-Freedom(TM)
PR Newswire - Wed Mar 11, 7:00AM CDT
Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced Manzo Pharmaceuticals has identified Medicus Research to perform the human clinical study of Lacto-Freedom probiotic, a necessary step in order to take the ground breaking product to market.
Manzo Pharmaceuticals announces progress, as retail stores start to carry Tummy Relief.
PR Newswire - Mon Mar 09, 8:00AM CDT
Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced its first retail product, Tummy Relief(TM) is now carried at Esterbrook Pharmacy in Reading, Pennsylvania, as the start of a major push into brick and mortar retail.
Manzo Pharmaceuticals Announces Positive Results From Laboratory Study of Lacto-Freedom Probiotic
PR Newswire - Tue Feb 03, 9:00AM CST
Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced positive results from the six month animal study of Lacto-Freedom(TM), the company's lactase producing probiotic. This successful testing brings Manzo Pharmaceuticals, and partner, Celprogen, Inc., one step closer to human clinical trials.
Manzo Pharmaceuticals begins retail distribution of products with independent pharmacies
PR Newswire - Wed Nov 12, 9:00AM CST
Manzo Pharmaceuticals, Inc. (OTCPink:MNZO), today announced that Manzo's Tummy Relief(TM) for babies is now being sold at Alitons Pharmacy drug stores in New York and Pennsylvania, and at The Medicine Shoppe in Milford Pennsylvania. Kenneth Manzo, CEO, stated that this is the beginning stage of promoting his product and is seeking to have it sold by major chain stores. Although Mr. Manzo already had a relationship with Aliton's, he is also in talks with Walgreens and others to have the product sold through their online properties as well as their brick and mortar locations throughout the United States.
Manzo Pharmaceuticals solidifies deal with USA based manufacturers to begin producing the company's lactose intolerance probiotic, Lacto-Freedom
PR Newswire - Thu Mar 24, 6:00AM CDT
Manzo Pharmaceuticals, Inc. (OTCPink:MNZO), today announced that it has solidified deals with GMP and FDA approved, USA based firms to handle manufacturing, and encapsulating and packaging the company's Lacto-Freedom(TM) probiotic.
Attention Shareholders: Manzo Pharmaceuticals Due Diligence Report - BrokerBank Securities
PR Newswire - Mon Oct 19, 7:15AM CDT
Manzo Pharmaceuticals, Inc. (OTCBB: MNZO) closed the trading at $.0007 up 133% on October 15th and promptly returned 28% on the following day. MNZO shares traded between $.001 and $.0017 for most of this year before hitting a low of $.0001 earlier this month.
Manzo Pharmaceuticals starts human laboratory testing of the company's lactose intolerance probiotic, Lacto-Freedom(TM)
PR Newswire - Thu Oct 15, 8:00AM CDT
Manzo Pharmaceuticals, Inc. (OTCPink:MNZO), today announced that in conjunction with Celprogen, Inc., the human laboratory testing of the company's exciting probiotic, Lacto-Freedom(TM) has begun. Celprogen has started sending out the test samples of the product marking the start of the much anticipated human testing, which is the last major step before the product can be manufactured and released to the public.
Manzo Pharmaceuticals announces exciting new product release as the company prepares for the full-scale human study of its Lacto-Freedom product to begin
PR Newswire - Mon Jun 08, 6:00AM CDT
Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced Manzo Pharmaceuticals has finished the development of its newest product, a natural sleep aid that the company has named Somnaid(TM). This news comes at the same time that Manzo Pharmaceuticals acknowledges positive results on its preliminary human study, and is now preparing to begin its full-scale human study of the company's ground breaking lactose intolerance product, Lacto-Freedom(TM).
Manzo Pharmaceuticals Announces Plans for Human Clinical Studies of the Company's Patented Lactose Intolerance Probiotic, Lacto-Freedom(TM)
PR Newswire - Wed Mar 11, 7:00AM CDT
Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced Manzo Pharmaceuticals has identified Medicus Research to perform the human clinical study of Lacto-Freedom probiotic, a necessary step in order to take the ground breaking product to market.
Manzo Pharmaceuticals announces progress, as retail stores start to carry Tummy Relief.
PR Newswire - Mon Mar 09, 8:00AM CDT
Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced its first retail product, Tummy Relief(TM) is now carried at Esterbrook Pharmacy in Reading, Pennsylvania, as the start of a major push into brick and mortar retail.
Manzo Pharmaceuticals Announces Positive Results From Laboratory Study of Lacto-Freedom Probiotic
PR Newswire - Tue Feb 03, 9:00AM CST
Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced positive results from the six month animal study of Lacto-Freedom(TM), the company's lactase producing probiotic. This successful testing brings Manzo Pharmaceuticals, and partner, Celprogen, Inc., one step closer to human clinical trials.
Manzo Pharmaceuticals begins retail distribution of products with independent pharmacies
PR Newswire - Wed Nov 12, 9:00AM CST
Manzo Pharmaceuticals, Inc. (OTCPink:MNZO), today announced that Manzo's Tummy Relief(TM) for babies is now being sold at Alitons Pharmacy drug stores in New York and Pennsylvania, and at The Medicine Shoppe in Milford Pennsylvania. Kenneth Manzo, CEO, stated that this is the beginning stage of promoting his product and is seeking to have it sold by major chain stores. Although Mr. Manzo already had a relationship with Aliton's, he is also in talks with Walgreens and others to have the product sold through their online properties as well as their brick and mortar locations throughout the United States.
